November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Silvia Escribano Serrat Explores A Potential Role of EASIX as a Predictor of Refractoriness and Mortality in iTTP
Nov 17, 2025, 17:26

Silvia Escribano Serrat Explores A Potential Role of EASIX as a Predictor of Refractoriness and Mortality in iTTP

Silvia Escribano Serrat, Research Fellow at Memorial Sloan Kettering Cancer Center, shared on LinkedIn:

”I am pleased to share this multicenter article on the potential role of EASIX as a predictor of refractoriness and mortality in iTTP.”

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a severe thrombotic microangiopathy caused by profound ADAMTS13 deficiency; although caplacizumab speeds platelet recovery, about 15% of patients remain refractory and may experience persistent endothelial or microvascular injury.

This study assessed whether the Endothelial Activation and Stress Index (EASIX) can track endothelial dysfunction and predict refractoriness or mortality in iTTP.

Read the full article here.

Article: EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura

Authors: Silvia Escribano Serrat, María Queralt Salas, Cristina Pascual-Izquierdo, Manuel Fernández Villalobos, Inés Gómez-Seguí, Teresa Fidalgo, Marta Fernández Docampo, Jorge Martínez Nieto, Óscar Lamas, Miquel Lozano, Joan Cid, Paola Charry, Marc Pino, Patricia Molina, Blanca De Moner, Álex Ramos, Ana Belén Moreno-Castaño, Julia Martínez-Sánchez, Ginés Escolar, Maribel Díaz-Ricart

Silvia Escribano Serrat Explores A Potential Role of EASIX as a Predictor of Refractoriness and Mortality in iTTP

Stay updated on all scientific advances with Hemostasis Today.